Top 5 Warren Buffett Stocks To Own For 2019

Aniruddha Meher

“If past history was all there was to the game, the richest people would be librarians.”

– Warren Buffett

Investing, particularly investing well, is not the easiest game in the world. It requires a multitude of virtues like patience, keeping faith in your investment and the important ability to admit it when a mistake has been made. Even the doyen of investing Warren Buffett admitted he made a mistake about his Berkshire stock saying

“I’ve made lots of dumb decisions. That’s part of the game.”

There are a few basics that are vital to hold on to while investing. So much so, we believe it would be nearly impossible to be successful in the field without these four building blocks of investment.

related news Market Crash: 5 essentials while reviewing your equity and mutual fund portfolio Budget 2018: LTCG and DDT; is there need to restructure your portfolio?

1. Set the right goals

Top 5 Warren Buffett Stocks To Own For 2019: US Ecology, Inc.(ECOL)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on US Ecology (ECOL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Shares of US Ecology Inc (NASDAQ:ECOL) have been assigned an average rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $70.80.

  • [By Ethan Ryder]

    US Ecology Inc (NASDAQ:ECOL) Director Daniel Fox sold 900 shares of the firm’s stock in a transaction on Friday, August 24th. The stock was sold at an average price of $72.15, for a total value of $64,935.00. Following the transaction, the director now owns 5,140 shares in the company, valued at $370,851. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Logan Wallace]

    BidaskClub upgraded shares of US Ecology (NASDAQ:ECOL) from a hold rating to a buy rating in a research note released on Thursday.

    Other equities research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of US Ecology from a hold rating to a buy rating in a research report on Thursday, April 12th. Zacks Investment Research cut shares of US Ecology from a strong-buy rating to a hold rating in a research report on Tuesday, April 10th. Finally, UBS Group started coverage on shares of US Ecology in a research report on Wednesday, March 14th. They issued a sell rating and a $55.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $58.80.

  • [By Motley Fool Transcribers]

    US Ecology Inc  (NASDAQ:ECOL)Q4 2018 Earnings Conference CallFeb. 22, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Warren Buffett Stocks To Own For 2019: CRB Futures Index(CR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Crew Energy Inc (TSE:CR) – Cormark issued their Q1 2020 EPS estimates for shares of Crew Energy in a research note issued on Tuesday, March 5th. Cormark analyst A. Arif expects that the company will earn $0.06 per share for the quarter. Cormark also issued estimates for Crew Energy’s Q2 2020 earnings at $0.02 EPS, Q3 2020 earnings at $0.02 EPS and Q4 2020 earnings at $0.03 EPS.

  • [By Shane Hupp]

    BlackRock Inc. grew its stake in Crane Co. (NYSE:CR) by 2.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,303,084 shares of the conglomerate’s stock after acquiring an additional 93,264 shares during the period. BlackRock Inc. owned 7.21% of Crane worth $399,069,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Crew Energy (TSE:CR) had its price objective lowered by equities research analysts at Canaccord Genuity from C$4.50 to C$4.00 in a report issued on Tuesday. Canaccord Genuity’s price objective indicates a potential upside of 101.01% from the stock’s previous close.

Top 5 Warren Buffett Stocks To Own For 2019: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Keith Speights]

    Three biotech stocks that have profited tremendously from their virtual monopolies are Alexion Pharmaceuticals (NASDAQ:ALXN), BioMarin Pharmaceutical (NASDAQ:BMRN), and Vertex Pharmaceuticals (NASDAQ:VRTX). Do these biotechs’ market positions make them winners for investors over the long run?

  • [By ]

    Alexion Pharmaceuticals Inc. (ALXN) is a U.S. pharma stock best known for its development of rare blood disorder drug Soliris. So far this drug has proved extremely successful. And now, the company is looking to expand into further treatment opportunities. The company is on the verge of snapping up Sweden’s Wilson Therapeutics for $855 million, further boosting (and diversifying) its rare disease lineup.

  • [By Shane Hupp]

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) gapped up before the market opened on Tuesday after Stifel Nicolaus raised their price target on the stock from $130.00 to $136.00. The stock had previously closed at $127.35, but opened at $128.69. Stifel Nicolaus currently has a hold rating on the stock. Alexion Pharmaceuticals shares last traded at $128.94, with a volume of 50491 shares.

  • [By Ethan Ryder]

    WARNING: “AGF Investments Inc. Takes $443,000 Position in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at www.tickerreport.com/banking-finance/4188611/agf-investments-inc-takes-443000-position-in-alexion-pharmaceuticals-inc-alxn.html.

  • [By Chris Lange]

    Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is breaking out from a bullish continuation pattern after completing a 2-year+ consolidation bottom. Upside is seen to the $200 area. Celgene Corp. (NASDAQ: CELG), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), and Incyte Corp. (NASDAQ: INCY) have weaker technical patterns and may have further downside risks. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is forming a potential bearish top – a move below $77.98 would open $71 to the $60 area.

  • [By Shane Hupp]

    These are some of the headlines that may have effected Accern’s scoring:

    Get Alexion Pharmaceuticals alerts:

    Q2 2018 EPS Estimates for Alexion Pharmaceuticals, Inc. Boosted by Analyst (ALXN) (americanbankingnews.com) What to Expect from Alexion Pharmaceuticals’ Q2 2018 Earnings (finance.yahoo.com) Why Most Analysts Recommend a ‘Buy’ for Alexion Stock (finance.yahoo.com) Alexion Pharmaceuticals’ Diversification Strategy Makes It A Solid Buy For 2018 (seekingalpha.com) Alexion Pharmaceuticals (ALXN) Scheduled to Post Quarterly Earnings on Wednesday (americanbankingnews.com)

    ALXN opened at $135.16 on Friday. The stock has a market cap of $30.06 billion, a P/E ratio of 26.19, a price-to-earnings-growth ratio of 1.21 and a beta of 1.08. Alexion Pharmaceuticals has a fifty-two week low of $102.10 and a fifty-two week high of $149.34. The company has a current ratio of 3.35, a quick ratio of 2.86 and a debt-to-equity ratio of 0.33.

Top 5 Warren Buffett Stocks To Own For 2019: MutualFirst Financial Inc.(MFSF)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on MutualFirst Financial (MFSF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on MutualFirst Financial (MFSF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    MutualFirst Financial, Inc. (NASDAQ:MFSF) – Stock analysts at DA Davidson increased their Q3 2018 earnings per share (EPS) estimates for shares of MutualFirst Financial in a research report issued to clients and investors on Monday, July 30th. DA Davidson analyst K. Reevey now forecasts that the bank will earn $0.68 per share for the quarter, up from their previous forecast of $0.62. DA Davidson has a “Neutral” rating on the stock. DA Davidson also issued estimates for MutualFirst Financial’s Q4 2018 earnings at $0.69 EPS, FY2018 earnings at $2.55 EPS and FY2019 earnings at $2.79 EPS.

  • [By Ethan Ryder]

    Media coverage about MutualFirst Financial (NASDAQ:MFSF) has trended somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MutualFirst Financial earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news articles about the bank an impact score of 47.9474560000459 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 5 Warren Buffett Stocks To Own For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

  • [By Motley Fool Transcribers]

    Ultragenyx Pharmaceutical Inc  (NASDAQ:RARE)Q4 2018 Earnings Conference CallFeb. 19, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

Leave a Reply

Your email address will not be published. Required fields are marked *